Therapeutic advances in the management of hepatitis B and hepatitis C

Current Opinion in Infectious Diseases

Volumn 14, Issue 5, 2001, Pages 593-601

  Nguyen, Mindie H ^a   Wright, Teresa L ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FIALURIDINE; INTERLEUKIN 10; LAMIVUDINE; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIDARABINE;

CLINICAL TRIAL; DEPRESSION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; NEPHROTOXICITY; REVIEW; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0034816344     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200110000-00014     Document Type: Review

References (88)

1. Viral hepatitis A through E
2. Epidemiology of hepatitis C: Geographic difference and temporal trends
3. Hepatitis C
4. The natural history of asymptomatic hepatitis B surface antigen carriers
5. Chronic hepatitis B virus infection: Treatment strategies for the new millennium
6. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
7. A randomized, controlled trial of interferon α-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
8. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
9. Long-term remission of chronic hepatitis B after α-interferon therapy
10. Interferon alfa therapy in patients with chronic hepatitis B virus infection: Effects on hepatitis B virus DNA in the liver
11. Long-term follow-up of the HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
12. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European concerted action on Viral Hepatitis (EUROHEP)
13. The long-term outcome of interferon-alpha treated and untreated patients with HBsAg-negative chronic hepatitis B
14. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
15. Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial
16. Psychiatric complications of long-term interferon alfa therapy
17. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus
18. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictor factors
19. A preliminary trial of lamivudine for chronic hepatitis B infection
20. Lamivudine as initial treatment for chronic hepatitis B in the United States
21. A one-year trial of lamivudine for chronic hepatitis
22. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
23. Acute exacerbation and hepatitis B clearance after emergence of YMDD motif mutation during lamivudine therapy
24. Pretherapy alanine transferase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
25. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
26. Long-term therapy of chronic hepatitis B with lamivudine
27. Clinical relevance of hepatitis B viral mutation
28. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
29. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
30. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
31. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for four years
32. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
33. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
34. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis
35. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: For whom and when?
36. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
37. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
38. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
39. A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
40. Successful orthotopic liver transplantation for lamivudine-resistant YMDD mutant virus
41. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study
42. Combination chemotherapy for hepatitis B virus: The final solution?
43. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo controlled phase II studies
44. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
45. A study of oral entecavir given for 28 days in both treatment-naïve and pre-treated subjects with chronic hepatitis
46. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
47. Hepatitis B virus (HBV) activity and pharmacokinetics of FTC in a 2 month trial in HBV infected patients
48. Hepatic failure and lactic acidosis due to fialuridine (FIAU): An investigational nucleoside analogue for chronic hepatitis B
49. Acute hepatitis C
50. Natural history of liver fibrosis progression in patients with chronic hepatitis C
51. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
52. 45-Year follow-up of hepatitis C virus infection in healthy young adults
53. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
54. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975
55. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A national heart, lung, and blood institute collaborative study
56. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
57. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the southwestern United States
58. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C
59. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
60. Therapy of hepatitis C: Meta-analysis of interferon alpha-2b trials
61. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
62. Long-term histologic improvement and loss detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy
63. Long-term follow-up study of sustained biochemical responders with interferon therapy
64. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
65. Treatment of hepatocellular carcinoma
66. Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics
67. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment
68. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
69. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
70. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
71. Early prediction of response in interferon monotherapy in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus AL
72. Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment
73. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
74. Interferon alfa-2b and ribavirin combination therapy in liver transplant recipients with recurrent hepatitis C
75. Combination of interferon alfa-2b plus ribavirin for recurrent hepatitis C infection after liver transplantation: A randomized controlled study
76. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-interferon) and may explain its enhanced efficacy in chronic hepatitis C (CHC)
77. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
78. Evaluation of the safety and efficacy of once-weekly PEG/interferon alfa-2a (Pegasys TM) for chronic hepatitis C: A multinational, randomized study
79. Peginterferon alfa-2a in patients with chronic hepatitis C
80. Pegylated interferon alfa-2b (PEG-Intron) monotherapy is superior to interferon alfa-2b (Intron A) for the treatment of chronic hepatitis C
81. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
82. Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN alfa-2a (PEGASYS) or standard interferon alfa-2b/ribavirin (REBETRON) combination therapy
83. Pegylated alfa-2a and ribavirin combination therapy for chronic hepatitis C: A phase II open-label study
84. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 Week treatment analysis of multicenter, multinational phase III randomized controlled trial
85. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
86. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy, and combination therapy relapsers
87. Interleukin-10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
88. Steatosis and chronic hepatitis C: Analysis of fibrosis and stellate cell activation